Contact Matthew Nojoomi
Summary: Gallstone disease affects approximately 10-15% of the adult population throughout the world. Patients develop pain and possible infection when stones block the cystic duct, preventing the gallbladder from emptying. In otherwise healthy patients, this condition is treated with relatively simple surgery (laparoscopic cholecystectomy), but in certain high-risk patient populations, surgery is not safe. Treatment options are limited for these patients and focus on relieving acute symptoms, but do not address the underlying cause of the disease, resulting in disease recurrence, additional clinical risk, and significant cost. ]] Icterō Medical is a medical device company that is committed to providing safe and definitive treatment to high-risk patients with gallstone disease. Our flagship product, the CholeSafe System, is a novel, catheter-based platform that provides definitive treatment for gallstone disease. The device easily integrates into the current workflow in the interventional radiology suite, allowing physicians to offer their patients the benefits of surgical treatment without the risk associated with general anesthesia.
Need: A way to safely and definitively treat gallstone disease in high risk patients with symptomatic gallstones in order to optimize patient outcomes and minimize associated costs.
Value: Our solution helps providers & hospitals definitively treat high-risk patients with gallstone disease by reducing costs and minimizing procedural complications.